pocketful logo light
pocketful logo light
Aurobindo Pharma Ltd logo

Aurobindo Pharma Ltd

NSE: AUROPHARMA BSE: 524804

₹1497.80

(3.75%)

Sun, 21 Jun 2026, 00:21 am

mtf coin illustrationMTF 5x

Aurobindo Pharma Share Price Live Chart

1 Day

(3.75%)

No Result Found

Summary

  • Market Cap (in Cr)

    83106.9

  • Net Profit (in Cr)

    3483.57

  • P/B

    2.06

  • Sector P/E

    33.76

  • P/E

    19.32

  • EV/EBITDA

    9.39

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    11.15

  • ROCE

    14.16

  • Debt/Equity

    0.24

  • EPS (TTM)

    61.09

  • Dividend Yield

    0

  • Book Value

    652.39

  • Interest Cover

    12.08

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are thoroughly covered by earnings (11.4x coverage).
  • Dividends after 3 years are expected to be thoroughly covered by earnings (12x coverage).
  • Aurobindo Pharma's earnings growth is expected to exceed the low risk savings rate of 7.2%.
  • Aurobindo Pharma's earnings are expected to exceed the low risk growth rate next year.
thumbs up icon

Cons

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Aurobindo Pharma's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Aurobindo Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for Aurobindo Pharma is expected to decrease over the next 2 years.
  • Aurobindo Pharma's earnings are expected to grow by 9.7% yearly, however this is not considered high growth (20% yearly).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters51.8251.8251.8251.8251.82
FII15.2413.9414.2114.3715.33
DII25.8727.6827.6026.9326.23
Public7.086.556.386.876.61
Government0000.000.00

Read More

Technical Analysis

RSI

59.92

MACD

1.68

50 DMA

1438.50

200 DMA

1238.98

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1813.801630.801528.601447.801345.601264.801081.80
Fibonacci1630.801560.891517.711447.801377.891334.711264.80
Camarilla1476.731459.951443.181447.801409.631392.851376.08

Pivots Level: Classic

R3

+366

1813.80

R2

+183

1630.80

R1

+80.80

1528.60

1447.80
1447.80
Pivot Point
LTP: 1497.80

S1

-102.20

1345.60

S2

-183

1264.80

S3

-366

1081.80

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1448.90

  • 20-EMA

    1449.62

  • 30-EMA

    1444.50

  • 50-EMA

    1421.45

  • 100-EMA

    1359.60

  • 200-EMA

    1289.06

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
21 May 2026board-meetingsAccounts
06 Apr 2026buyback
09 Feb 2026board-meetingsQuarterly Results, Nine Months Results
05 Nov 2025board-meetingsQuarterly Results
12 Aug 2025agm
04 Aug 2025dividend₹4.00 Dividend /Share08 Aug 2025
08 Jul 2025dividendInterim Dividend - Rs. - 408 Aug 2025
30 Jul 2024agm
26 Jul 2024agmAnnual General Meeting27 Aug 2024
18 Jul 2024buyback

Read More

Peer Comparison

Aurobindo Pharma Ltd logo

Aurobindo Pharma Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Aurobindo Pharma Ltd About

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1986

Headquarters

CEO

M R Kumar

Employees

Contact

Website icon

Website

http://www.aurobindo.com

Email icon

Email

cs@aurobindo.com; investorgrievances@aurobindo.com

Phone icon

Phone

91-40-23736370

Location icon

Location

Plot No 2 Maitrivihar, Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, 500038

Read More

Aurobindo Pharma Ltd Company History

YearHistory
2020
  • Tied up with BIRAC to develop COVID-19 vaccine.
  • Collaborated with CSIR to develop COVID-19 vaccine.
  • Signed exclusive licensing agreement with COVAXX.
2021
  • Received USFDA approval for Droxidopa Capsules.
  • Received NCLT approval for scheme of amalgamation.
2022
  • Acquired 51% stake in GLS Pharma Limited.
  • Arm received final USFDA approval for Vasopressin injection.
  • Arm received USFDA approval for Triamcinolone Acetonide injectable suspension.
2023
  • Arm received USFDA approval for cancer drug.
  • To launch HIV triple combination product for children under ViiV Healthcare licence.
2024
  • Received first USFDA approval for Lidocaine Hydrochloride Injection.
  • Commissioned four plants in Andhra Pradesh including Pen-G facility.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GOLDMAN SACHS BANK EUROPESE - ODIblockBuy106228110716 Oct 2025
GOLDMAN SACHS (SINGAPORE) PTE.- ODIblockSell106228110716 Oct 2025
MARSHALL WACE INVESTMENT STRATEGIESGTOPS FUNDblockBuy275711160.125 Jan 2024
MARSHALL WACE INVESTMENT STRATEGIES - SYSTEMATIC ALPHA PLUS FUNDblockBuy159501160.125 Jan 2024
BNP PARIBAS ARBITRAGEblockSell1500011160.125 Jan 2024
MARSHALL WACE INVESTMENT STRATEGIES SYSTEMATIC ALPHA PLUS FUNDblockBuy8621160.125 Jan 2024
MARSHALL WACE INVESTMENT STRATEGIES - EUREKA FUNDblockBuy1064801160.125 Jan 2024
SOCIETE GENERALEblockBuy14843231160.125 Jan 2024
BNP PARIBAS ARBITRAGEblockSell14843231160.125 Jan 2024
MARSHALL WACE INVESTMENT STRATEGIES EUREKA FUNDblockBuy536411160.125 Jan 2024

Read More

Aurobindo Pharma Ltd News

Aurobindo Pharma promoter encumbrance status

Promoters of Aurobindo Pharma confirm no new encumbrances on shares as of March 31, 2026, beyond prior disclosures.

20 Jun 2026

companies

Aurobindo Pharma gets US FTC nod for Lannett buy

Aurobindo Pharma USA Inc secured US FTC approval to acquire 100% of Lannett Company LLC. The deal is set to close by June 30, 2026.

19 Jun 2026

companies

US FDA Tags Aurobindo's Eugia Unit-III as OAI

The US FDA has classified Aurobindo Pharma's Eugia Unit-III facility as Official Action Indicated (OAI) following an inspection that identified 11 findings.

12 Jun 2026

companies

Aurobindo Pharma to attend Goldman Sachs meet

Aurobindo Pharma officials will attend a Goldman Sachs investor meeting in Hyderabad on June 12, 2026. No unpublished price sensitive information will be discussed.

09 Jun 2026

companies

Aurobindo Pharma to attend UBS investor meet

Aurobindo Pharma officials will attend a virtual investor meeting hosted by UBS on June 10, 2026. No unpublished price sensitive information will be discussed.

05 Jun 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number